Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042796 | 1.00 | CNR2 (0.47) | CNR2FGFR1FGFR4PDE10AATR | |
| SCHEMBL5048235 | 0.88 | CNR2 (0.50) | CNR2FGFR1FGFR4PDE10ACYP11B2 | |
| SCHEMBL5048229 | 0.88 | CNR2 (0.50) | CNR2FGFR1FGFR4PDE10ACYP11B2 | |
| SCHEMBL5048207 | 0.88 | CNR2 (0.53) | CNR2FGFR1FGFR4PDE10ACYP11B2 | |
| SCHEMBL5048199 | 0.88 | CNR2 (0.53) | CNR2FGFR1FGFR4PDE10ACYP11B2 | |
| SCHEMBL5046851 | 0.85 | CNR2 (0.45) | CNR2ATRCFTRHPGD | |
| SCHEMBL5046854 | 0.85 | CNR2 (0.45) | CNR2ATRCFTRHPGD | |
| SCHEMBL5043117 | 0.82 | CNR2 (0.43) | CNR2PDE10AATRCYP11B2CFTR | |
| SCHEMBL5043122 | 0.82 | CNR2 (0.43) | CNR2PDE10AATRCYP11B2CFTR | |
| SCHEMBL5048370 | 0.81 | HSD17B3 (0.48) | CYP11B2HSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725565-B1 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B1, HSD17B2 | CNR2 3942/4885FGFR1 2215/4885FGFR4 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.